ISSN (Print): 1568-0096
ISSN (Online): 1873-5576
Volume 21, 11 Issues, 2021
Download PDF Flyer
Open Access Funding
Promote Your Article
ISSN (Print): 1568-0096
ISSN (Online): 1873-5576
Aims & Scope
Science Citation Index Expanded™ (SciSearch®), Journal Citation Reports/Science Edition, InCites, Index to Scientific Reviews®, Biochemistry & Biophysics Citation Index®, Biotechnology Citation Index®, ISI Alerting Service, Prous Science Integrity, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE, Chemical Abstracts Service/SciFinder, Cambridge Scientific Abstracts (CSA)/ProQuest, Scilit, ChemWeb, Google Scholar, BIOBASE, MediaFinder®-Standard Periodical Directory, Genamics JournalSeek, PubsHub, Index Copernicus, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, British Library, Ulrich's Periodicals Directory, JournalTOCs, QOAM, ERA 2018 and Dimensions.
Ranking and Category:
Submit Abstracts / Manuscripts Online
Animated Abstract Submission
View Full Editorial Board
5 - Year: 2.947
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
Editor(s): Liang Qiao
Co-Editor(s): Yumin Li, Xiang Yan and Jacob George
eISBN: 978-1-60805-072-7, 2012
Therapeutic options for late-stage liver cancer are very limited and the prognosis is often poor. A better understanding of the molecular mechanisms involved in the initiation, progression, and metastasis of hepatocellular carcinoma is critical for developing more rational diagnostic and therapeutic approaches. This e-book covers current developments on clinically relevant research on the molecular biology of hepatocellular carcinoma. It should be a valuable reference for professional gastroenterologists, hepatologists and oncologists as well as medical students and researchers.
Editor(s): Estela Maria Novak and Eduardo Magalhães Rego
eISBN: 978-1-60805-259-2, 2012
The number of new discoveries related to diagnostics and therapeutics of hematological cancer is significant. These have resulted in continuous progress in fundamental knowledge about molecular and cellular mechanisms in hematological neoplasia. Physiopathogenesis of Hematological Cancer presents a concise overview of the cellular and molecular biology of myelo- and Lymphoproliferative disorders. The expert reviews presented within this e-book are also accompanied by bibliographic references for relevant scientific literature. This book should prove to be a valuable reference tool for both medical graduate and postgraduates in the field of oncology.
Editor(s): Javier Camacho
eISBN: 978-1-60805-016-1, 2012
Cancer is one of the major causes of death worldwide. Despite hundreds of clinical trials currently in progress for cancer patients, the success rate is still very low. Understanding the molecular aspects of cancer development, the discovery of new molecular targets and rational drug design on this molecular basis should help in discovering early cancer biomarkers as well as novel therapeutic drugs.
This book describes various cancer topics on a molecular level and integrates information on the relationship between causes of cancer, cancer cell biology, metastasis, cancer prevention and drug design. This book should prove to be an extraordinary reference text for students, physicians and oncologists.
Editor(s): Klaus Podar and Kenneth C. Anderson
eISBN: 978-1-60805-297-4, 2012
Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cells and the bone marrow microenvironment, have already fundamentally changed treatment options of this disease. Indeed, their benefit is now not only shown in relapsed and refractory disease but they also improve overall response, duration of response, and progression-free and overall survival when used as part of first-line regimens. However, despite new insights into MM pathogenesis and exciting derived therapeutic advances, MM still remains incurable. Ongoing studies are therefore aiming to further delineate mechanisms of MM pathogenesis within the bone marrow to identify novel agents with enhanced cytotoxicity and decreased drug resistance to improve patient outcome.
Multiple Myeloma - A New Era of Treatment Strategies is devoted to contributions from eminent scientists providing readers with comprehensive accounts of the most recent developments in the field of MM research. It addresses the interests of scientists and clinical investigators in MM research as well as other fields of oncology, in which the microenvironment is believed to play an important role.
Editor(s): Misa Nakamura and Kennichi Kakudo
eISBN: 978-1-60805-073-4, 2010
The WHO report estimates that 12 million people will be diagnosed with some form of cancer this year. In addition, the report predicts that more than 7 million people will die early from the disease. Together, the number of cancer cases and deaths from cancer are expected to increase by one percent each year. Cancer research has seen remarkable advancements, including the multi-step carcinogenesis theory and the identification of a cancer stem cell. These advancements are being applied to clinical therapies targeting the oncogene. In addition, the function of the gene product is becoming clear through analysis of the intracellular signaling of the oncogene. As a result, it has become clear that the morphologies of the cancers depend on the kind of the abnormal gene. Of course, these differences would influence patient’s life and death and is summarized by specialists in this area. This theme includes the full range of human diseases regarding medical genetics, biochemistry, microbiology, immunology, anatomy, pathology, structural biology, molecular cell biology, neuroscience and developmental biology. The eBook contains articles written by specialists in this area. It should prove to be of great use to clinicians and scientists in all medical fields.
Author(s): Lawrence M. Agius
eISBN: 978-1-60805-266-0, 2011
This e-book explains the essential role of angiogenesis in the progression and spread of the neoplasm, including the mechanics of initial carcinogenesis in promoting malignant transformation. The e-book deals with specific categories or subtypes of tumors with some emphasis on astrocytomas and glioblastoma multiforme. The process of carcinogenesis has been re-interpreted in terms of deranged physiologic principles and hence reference is made to what upsets homeostatic mechanisms. Readers of this e-book will have an opportunity to appreciate the essential role of angiogenesis not only in progression and spread of the neoplasm but especially also in the mechanics of initial carcinogenesis in promoting malignant transformation. This e-book should be a useful reference for scholars and clinicians interested in learning about cancer pathophysiology.
Editor(s): Domenico Ribatti
eISBN: 978-1-60805-004-8, 2009
The book presents recent advances in the field of angiogenesis and antiangiogenesis. Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research now has a solid scientific foundation. Tumor growth, metastasis, progression, dormancy and apoptosis depend on angiogenesis: several clinical studies have shown a positive correlation between the number of vessels in the tumor, metastasis formation and disease prognosis. A number of approaches have been developed to inhibit tumor angiogenesis, and numerous compounds discovered that inhibit angiogenesis, but only a few of them proved effective in vivo and only a couple of agents were able to induce tumor regression. These and other related developments described in the book should prove to be of interest to a large number of readers wishing to keep abreast with the latest developments in the field.
Editor(s): Thomas C. Chen
Co-Editor(s): Marc Chamberlain
eISBN: 978-1-60805-132-8, 2010
ISBN: 978-1-60805-519-7 ISSN: 2210-5565 (Print)
Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconclusive because of the limited number of patients involved. As a result, many controversies exist in neuro-oncology drug development for which a forum does not exist. This ebook presents a detailed account on the use of avastin in treating cancer patients. A discussion on clinical experiences and the controversial debate among researchers of avastin's role in restricting malignant gliomas is also included giving readers a diverse perspective on the rationale of treating CNS tumors.
Editor(s): Adit Ben-Baruch
eISBN: 978-1-60805-256-1, 2012
Tumor development and progression are multi-factorial processes, in which genomic alterations and modifications in gene expression in pre-malignant cells are joined by deleterious microenvironmental factors. The tumor microenvironment contains stroma cells and leukocytes, soluble factors and matrix components. The intensive interplay that exists between the host factors and the tumor cells plays a major role in dictating the final outcome of the malignant process.
Inflammatory mediators are pivotal microenvironmental factors present in the tumor milieu. These inflammatory components support cell growth and invasion, induce mutagenesis, increase angiogenicity, and suppress potential anti-tumor immune functions. The inflammatory constituents that prevail in tumors include leukocytes and soluble mediators - cytokines and chemokines.
This e-book describes the roles played by these mediators in malignancy, and explains the basis for their consideration as therapeutic targets in cancer.
The e-book is a timely overview of the roles played by inflammatory soluble mediators in neoplastic diseases. The topics addressed in this volume serve as a handy reference to investigators studying basic aspects of the malignant tumor growth, to clinicians who wish to better understand the processes involved in malignancy, and to pharmacological professionals seeking novel candidates for therapeutic intervention in cancer.
Editor(s): Pier Paolo Claudio and Richard M. Niles
eISBN: 978-1-60805-447-3, 2012
Various estimates suggest that between 30-40% of all human cancers are related to dietary patterns. Strong epidemiological evidence from population and twin studies points to dietary constituents that either contribute or protect against the development of various forms of cancer.
This e-book reviews some traditional and relatively new areas of nutrition and cancer. Epidemiological data is combined with molecular biology research and, where available, clinical trial data. The emerging science of "Nutrigenomics" is discussed with chapters on the biological role of various nutrition components from red wine, peppers, green tea, fish oil, cruciferous vegetables, retinoids; and the intersection of nutrition and epigenetics in hematopoiesis.
This e-book will be of interest to researchers in the nutrition and cancer field, physicians in family and community medicine, internal medicine and oncology, as well as dieticians providing counseling to cancer patients and cancer survivors.
Editor(s): Atta-ur-Rahman and Khurshid Zaman
eISBN: 978-1-60805-478-7, 2012
ISBN: 978-1-60805-612-5 ISSN: 2213-3585 (Print)
The Topics in Anti-Cancer Research e-Book series covers important advances on both experimental (preclinical) and clinical cancer research in drug development.
Major developments in the fields of oncology are covered including mechanisms, tumor and stem cell biology, metastasis, tumor suppressors, cancer drug targets, drug clinical trials, cellular and molecular pathology, genomics and genetics, diagnostics, translational therapeutics, tumor immunology, and cancer prevention and epidemiology.
Topics in Anti-Cancer Research is an essential e-book series for oncologists, pharmaceutical scientists, clinicians, and to researchers in other related disciplines.
Editor(s): Atta-ur Rahman and Khurshid Zaman
eISBN: 978-1-60805-136-6, 2013
ISBN: 978-1-60805-139-7 ISSN: 2213-3585 (Print)
This is the second volume of the Patent eBook Series titled Topics in Anti-Cancer Research. The eBook includes updated chapters on topics relevant to contemporary cancer research published in the journal, Recent Patents on Anti-Cancer Drug Discovery.
This volume covers scientific and patented novel chemotherapeutic agents and drugs for metastatic castration-resistant prostate cancer and Ras/ Raf /MEK/ERK pathway, P1K, AKT and mTORC1/2 inhibitors, ATPase inhibitors for cancer therapy, and sphingomyelin biosynthesis which regulates cancer cell death and growth.
Other chapters also explain research on biochemical regulation i.e. cell cycle and energy metabolism, the role of genetic variations of FcγRs gamma receptors in monoclonal antibody based anti-cancer therapy and effectiveness of antiangiogenic therapy, endogenous angiogenesis inhibitors and anti-angiogenic drugs for the treatment of renal cell carcinoma, prevention of cancer by ribonucleotide reductase, anticancer activity of Erlotinib in glioblastoma and the mechanisms of action of nanodrugs and nano-sized camptothecin drugs in cancer chemotherapy. The volume also covers recent studies in the field of onconutrition. The broad range of topics covered in this second volume will be of immense interest to clinicians, scientists and R&D experts seeking new targets for the prevention of cancer, novel oncogenic biomarkers, and methods for cancer therapy.